SinoMab BioScience (HKSE:03681) Net Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. SinoMab BioScience's Net Income for the six months ended in Dec. 2023 was HK$-119.24 Mil. SinoMab BioScience's Revenue for the six months ended in Dec. 2023 was HK$0.00 Mil. Therefore, SinoMab BioScience's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for SinoMab BioScience's Net Margin % or its related term are showing as below:

HKSE:03681' s Net Margin % Range Over the Past 10 Years
Min: -17810.45 Med: -9461.3 Max: -1112.15
Current: -17810.45

HKSE:03681's Net Margin % is ranked worse than
93.57% of 1027 companies
in the Biotechnology industry
Industry Median: -151.78 vs HKSE:03681: -17810.45

SinoMab BioScience Net Margin % Historical Data

The historical data trend for SinoMab BioScience's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience Net Margin % Chart

SinoMab BioScience Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-1,112.15

-17,810.45

SinoMab BioScience Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial							-670.66	-	-	-9,823.98	-

Competitive Comparison of SinoMab BioScience's Net Margin %

For the Biotechnology subindustry, SinoMab BioScience's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SinoMab BioScience's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Net Margin % distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's Net Margin % falls into.

SinoMab BioScience Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

SinoMab BioScience's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-265.91	/	1.493
	=	-17,810.45 %

SinoMab BioScience's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-119.238	/	0
	=	%

SinoMab BioScience (HKSE:03681) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

SinoMab BioScience Net Margin % Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SinoMab BioScience (HKSE:03681) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG

Website

https://www.sinomab.com

SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.

Executives

Hainan Haiyao Co. Ltd.	2101 Beneficial owner
Liu Wenyi	2201 Interest of corporation controlled by you
Leung Shui On	2201 Interest of corporation controlled by you
Qiang Jing
West Biolake Holdings Limited	2101 Beneficial owner
Skytech Technology Limited	2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch	2106 Person having a security interest in shares
Xu Sijia	2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She	2106 Person having a security interest in shares
Apricot Oversea Holdings Limited	2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si	2101 Beneficial owner
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Hai Nan Hai Yao Gu Fen You Xian Gong Si	2101 Beneficial owner

SinoMab BioScience (HKSE:03681) Headlines

No Headlines